Skip to main content
Erschienen in: Die Dermatologie 12/2019

11.11.2019 | Wirkstoffe | Leitthema

Neue Entwicklungen bei Topika

verfasst von: Prof. Dr. Johannes Wohlrab

Erschienen in: Die Dermatologie | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Topika sind die mit Abstand am häufigsten durch den/die Dermatologen/-in eingesetzten therapeutischen oder prophylaktischen Präparationen. In den letzten Jahren haben allerdings nur wenige neue arzneiliche Wirkstoffe in Topika den Markt erreicht, dennoch sind innovative galenische Konzepte und Strategien zur Eigenwirkung von Topika entwickelt worden. So werden wir in den kommenden Jahren auch mit neuen und echten Innovationen im Bereich der Topika rechnen können. Es ist zu erwarten, dass insbesondere neue kleinmolekulare, aber auch biologische Arzneistoffe durch Topika insbesondere bei entzündlichen Indikationen verfügbar sein werden. Zudem sind innovative Strategien zur Substitution bzw. Regulation der physikochemischen und mikrobiologischen Barrierefunktion zu erwarten. In weiterer Zukunft ergeben sich zudem völlig neue Optionen im Rahmen der Applikation von Ribonukleinsäurederivaten selbst oder deren Hemmstoffe für die gezielte Einflussnahme auf die Genexpression. Insgesamt kann festgestellt werden, dass durch moderne Vehikelstrategien und Verfahren zur gezielten Eigenwirkung von Topika das Potenzial der epikutanen Applikation erheblich weiterentwickelt wird und auch die Fortschritte in der Biotechnologie und Physikochemie verstärkt praktische Relevanz erlangen werden.
Literatur
1.
Zurück zum Zitat Wohlrab J, Staubach P, Augustin M, Eisert L, Hunerbein A, Nast A, Reimann H, Stromer K, Mahler V (2018) S2k guidelines for the use of topical preparations on the skin. J Dtsch Dermatol Ges 16:376–392PubMed Wohlrab J, Staubach P, Augustin M, Eisert L, Hunerbein A, Nast A, Reimann H, Stromer K, Mahler V (2018) S2k guidelines for the use of topical preparations on the skin. J Dtsch Dermatol Ges 16:376–392PubMed
2.
Zurück zum Zitat Surber C, Knie U (2018) Metamorphosis of vehicles: mechanisms and opportunities. Curr Probl Dermatol 54:152–165PubMed Surber C, Knie U (2018) Metamorphosis of vehicles: mechanisms and opportunities. Curr Probl Dermatol 54:152–165PubMed
3.
Zurück zum Zitat Wohlrab J (2014) Grundlagen der topischen Therapie. Hautarzt 65:169–174PubMed Wohlrab J (2014) Grundlagen der topischen Therapie. Hautarzt 65:169–174PubMed
7.
Zurück zum Zitat Wohlrab J, Michael J (2018) Dapsone for topical use in extemporaneous preparations. J Dtsch Dermatol Ges 16:34–40PubMed Wohlrab J, Michael J (2018) Dapsone for topical use in extemporaneous preparations. J Dtsch Dermatol Ges 16:34–40PubMed
8.
Zurück zum Zitat Wohlrab J, Gilbrich F, Wolff L, Fischer M, Philipp S (2017) Präklinische Validierung der Sicherheit von Chloralhydrat zur topischen Applikation am Beispiel des psoriatischen Pruritus. Hautarzt 68:217–223PubMed Wohlrab J, Gilbrich F, Wolff L, Fischer M, Philipp S (2017) Präklinische Validierung der Sicherheit von Chloralhydrat zur topischen Applikation am Beispiel des psoriatischen Pruritus. Hautarzt 68:217–223PubMed
9.
Zurück zum Zitat Cinar SL, Kartal D, Bayram AK, Canpolat M, Borlu M, Ferahbas A, Per H (2017) Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis. Indian J Dermatol Venereol Leprol 83:27–32PubMed Cinar SL, Kartal D, Bayram AK, Canpolat M, Borlu M, Ferahbas A, Per H (2017) Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis. Indian J Dermatol Venereol Leprol 83:27–32PubMed
10.
Zurück zum Zitat Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, Katayama I (2017) Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol 153:39–48PubMed Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, Katayama I (2017) Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol 153:39–48PubMed
11.
Zurück zum Zitat Wohlrab J, Neubert RH, Michael J, Naumann S (2015) Methotrexate for topical application in an extemporaneous preparation. J Dtsch Dermatol Ges 13:891–901PubMed Wohlrab J, Neubert RH, Michael J, Naumann S (2015) Methotrexate for topical application in an extemporaneous preparation. J Dtsch Dermatol Ges 13:891–901PubMed
12.
Zurück zum Zitat Ma JE, Ernste FC, Davis MDP, Wetter DA (2019) Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: The mayo clinic experience, 2012–2017. Clin Exp Dermatol 44:e189–e192PubMed Ma JE, Ernste FC, Davis MDP, Wetter DA (2019) Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: The mayo clinic experience, 2012–2017. Clin Exp Dermatol 44:e189–e192PubMed
13.
Zurück zum Zitat Rafael A, Torres T (2016) Topical therapy for psoriasis: a promising future. Focus on jak and phosphodiesterase‑4 inhibitors. Eur J Dermatol 26:3–8PubMed Rafael A, Torres T (2016) Topical therapy for psoriasis: a promising future. Focus on jak and phosphodiesterase‑4 inhibitors. Eur J Dermatol 26:3–8PubMed
14.
Zurück zum Zitat Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R (2017) Topical janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 77:167–170PubMed Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R (2017) Topical janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol 77:167–170PubMed
15.
Zurück zum Zitat Bokhari L, Sinclair R (2018) Treatment of alopecia universalis with topical janus kinase inhibitors—a double blind, placebo, and active controlled pilot study. Int J Dermatol 57:1464–1470PubMed Bokhari L, Sinclair R (2018) Treatment of alopecia universalis with topical janus kinase inhibitors—a double blind, placebo, and active controlled pilot study. Int J Dermatol 57:1464–1470PubMed
16.
Zurück zum Zitat Hosking AM, Juhasz M, Mesinkovska NA (2018) Topical janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol 79:535–544PubMed Hosking AM, Juhasz M, Mesinkovska NA (2018) Topical janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol 79:535–544PubMed
17.
Zurück zum Zitat Liu LY, Craiglow BG, King BA (2018) Tofacitinib 2 % ointment, a topical janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 78:403–404.e1PubMed Liu LY, Craiglow BG, King BA (2018) Tofacitinib 2 % ointment, a topical janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol 78:403–404.e1PubMed
18.
Zurück zum Zitat Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D (2017) Treatment of vitiligo with the topical janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 76:1054–1060.e1 Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D (2017) Treatment of vitiligo with the topical janus kinase inhibitor ruxolitinib. J Am Acad Dermatol 76:1054–1060.e1
19.
Zurück zum Zitat Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Gold SLF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (pde4) inhibitor for the topical treatment of atopic dermatitis (ad) in children and adults. J Am Acad Dermatol 75:494–503.e6PubMed Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Gold SLF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA (2016) Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (pde4) inhibitor for the topical treatment of atopic dermatitis (ad) in children and adults. J Am Acad Dermatol 75:494–503.e6PubMed
20.
Zurück zum Zitat Martin CJ, Alcock N, Hiom S, Birchall JC (2017) Development and evaluation of topical gabapentin formulations. Pharmaceutics 9(4):31PubMedCentral Martin CJ, Alcock N, Hiom S, Birchall JC (2017) Development and evaluation of topical gabapentin formulations. Pharmaceutics 9(4):31PubMedCentral
21.
Zurück zum Zitat Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T, Maurer M, Metz M (2018) Role of substance p and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derm Venereol 98:26–31PubMed Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T, Maurer M, Metz M (2018) Role of substance p and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derm Venereol 98:26–31PubMed
22.
Zurück zum Zitat Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, Quiring J, Drew J, Pariser DM (2019) A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol 20:593–604PubMedPubMedCentral Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, Quiring J, Drew J, Pariser DM (2019) A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol 20:593–604PubMedPubMedCentral
23.
Zurück zum Zitat Masur C, Soeberdt M, Kilic A, Knie U, Abels C (2019) Safety and efficacy of topical formulations containing 0.5, 1 and 2 % glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. https://doi.org/10.1111/bjd.18234 CrossRefPubMed Masur C, Soeberdt M, Kilic A, Knie U, Abels C (2019) Safety and efficacy of topical formulations containing 0.5, 1 and 2 % glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. https://​doi.​org/​10.​1111/​bjd.​18234 CrossRefPubMed
24.
Zurück zum Zitat Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA (2010) Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 17:388–399PubMedPubMedCentral Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA (2010) Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell 17:388–399PubMedPubMedCentral
26.
Zurück zum Zitat FDA (2018) Drug and device news. P T 43:13–30 FDA (2018) Drug and device news. P T 43:13–30
27.
Zurück zum Zitat Ng ZY, Kang GC, Chang CS, Por YC (2016) Efficacy of topical timolol as primary monotherapy in cutaneous facial infantile hemangiomas. J Craniofac Surg 27:e516–e520PubMed Ng ZY, Kang GC, Chang CS, Por YC (2016) Efficacy of topical timolol as primary monotherapy in cutaneous facial infantile hemangiomas. J Craniofac Surg 27:e516–e520PubMed
28.
Zurück zum Zitat Waldman RA, Lin G, Sloan B (2019) Clinical pearl: topical timolol for refractory hypergranulation. Cutis 104:118–119PubMed Waldman RA, Lin G, Sloan B (2019) Clinical pearl: topical timolol for refractory hypergranulation. Cutis 104:118–119PubMed
29.
Zurück zum Zitat Wu HW, Wang X, Zhang L, Zheng JW, Liu C, Wang YA (2018) Topical timolol vs. Oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol 8:605PubMedPubMedCentral Wu HW, Wang X, Zhang L, Zheng JW, Liu C, Wang YA (2018) Topical timolol vs. Oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol 8:605PubMedPubMedCentral
31.
Zurück zum Zitat Boge L, Hallstensson K, Ringstad L, Johansson J, Andersson T, Davoudi M, Larsson PT, Mahlapuu M, Hakansson J, Andersson M (2019) Cubosomes for topical delivery of the antimicrobial peptide ll-37. Eur J Pharm Biopharm 134:60–67PubMed Boge L, Hallstensson K, Ringstad L, Johansson J, Andersson T, Davoudi M, Larsson PT, Mahlapuu M, Hakansson J, Andersson M (2019) Cubosomes for topical delivery of the antimicrobial peptide ll-37. Eur J Pharm Biopharm 134:60–67PubMed
32.
Zurück zum Zitat Goebel AS, Schmaus G, Neubert RH, Wohlrab J (2012) Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part I: Carnosine. Skin Pharmacol Physiol 25:281–287PubMed Goebel AS, Schmaus G, Neubert RH, Wohlrab J (2012) Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part I: Carnosine. Skin Pharmacol Physiol 25:281–287PubMed
33.
Zurück zum Zitat Neubert RHH, Sommer E, Scholzel M, Tuchscherer B, Mrestani Y, Wohlrab J (2018) Dermal peptide delivery using enhancer moleculs and colloidal carrier systems. Part II: tetrapeptide PKEK. Eur J Pharm Biopharm 124:28–33PubMed Neubert RHH, Sommer E, Scholzel M, Tuchscherer B, Mrestani Y, Wohlrab J (2018) Dermal peptide delivery using enhancer moleculs and colloidal carrier systems. Part II: tetrapeptide PKEK. Eur J Pharm Biopharm 124:28–33PubMed
34.
Zurück zum Zitat Sommer E, Neubert RHH, Mentel M, Tuchscherer B, Mrestani Y, Wohlrab J (2018) Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part III: tetrapeptide GEKG. Eur J Pharm Sci 124:137–144PubMed Sommer E, Neubert RHH, Mentel M, Tuchscherer B, Mrestani Y, Wohlrab J (2018) Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part III: tetrapeptide GEKG. Eur J Pharm Sci 124:137–144PubMed
35.
Zurück zum Zitat Sae-Wong C, Mizutani N, Kangsanant S, Yoshino S (2016) Topical skin treatment with fab fragments of an allergen-specific IgG1 monoclonal antibody suppresses allergen-induced atopic dermatitis-like skin lesions in mice. Eur J Pharmacol 779:131–137PubMed Sae-Wong C, Mizutani N, Kangsanant S, Yoshino S (2016) Topical skin treatment with fab fragments of an allergen-specific IgG1 monoclonal antibody suppresses allergen-induced atopic dermatitis-like skin lesions in mice. Eur J Pharmacol 779:131–137PubMed
36.
Zurück zum Zitat Saleh B, Dhaliwal HK, Portillo-Lara R, Shirzaei Sani E, Abdi R, Amiji MM, Annabi N (2019) Local immunomodulation using an adhesive hydrogel loaded with mirna-laden nanoparticles promotes wound healing. Small 15:e1902232PubMed Saleh B, Dhaliwal HK, Portillo-Lara R, Shirzaei Sani E, Abdi R, Amiji MM, Annabi N (2019) Local immunomodulation using an adhesive hydrogel loaded with mirna-laden nanoparticles promotes wound healing. Small 15:e1902232PubMed
37.
Zurück zum Zitat Wang LL, Liu Y, Chung JJ, Wang T, Gaffey AC, Lu M, Cavanaugh CA, Zhou S, Kanade R, Atluri P, Morrisey EE, Burdick JA (2017) Local and sustained mirna delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischemic injury. Nat Biomed Eng 1:983–992PubMedCentral Wang LL, Liu Y, Chung JJ, Wang T, Gaffey AC, Lu M, Cavanaugh CA, Zhou S, Kanade R, Atluri P, Morrisey EE, Burdick JA (2017) Local and sustained mirna delivery from an injectable hydrogel promotes cardiomyocyte proliferation and functional regeneration after ischemic injury. Nat Biomed Eng 1:983–992PubMedCentral
38.
Zurück zum Zitat Maschmeyer P, Petkau G, Siracusa F, Zimmermann J, Zugel F, Kuhl AA, Lehmann K, Schimmelpfennig S, Weber M, Haftmann C, Riedel R, Bardua M, Heinz GA, Tran CL, Hoyer BF, Hiepe F, Herzog S, Wittmann J, Rajewsky N, Melchers FG, Chang HD, Radbruch A, Mashreghi MF (2018) Selective targeting of pro-inflammatory th1 cells by microrna-148a-specific antagomirs in vivo. J Autoimmun 89:41–52PubMedPubMedCentral Maschmeyer P, Petkau G, Siracusa F, Zimmermann J, Zugel F, Kuhl AA, Lehmann K, Schimmelpfennig S, Weber M, Haftmann C, Riedel R, Bardua M, Heinz GA, Tran CL, Hoyer BF, Hiepe F, Herzog S, Wittmann J, Rajewsky N, Melchers FG, Chang HD, Radbruch A, Mashreghi MF (2018) Selective targeting of pro-inflammatory th1 cells by microrna-148a-specific antagomirs in vivo. J Autoimmun 89:41–52PubMedPubMedCentral
40.
Zurück zum Zitat Lind M, Nielsen KT, Schefe LH, Norremark K, Eriksson AH, Norsgaard H, Pedersen BT, Petersson K (2016) Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb) 6:413–425 Lind M, Nielsen KT, Schefe LH, Norremark K, Eriksson AH, Norsgaard H, Pedersen BT, Petersson K (2016) Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb) 6:413–425
41.
Zurück zum Zitat Hsu T, Mitragotri S (2011) Delivery of sirna and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci U S A 108:15816–15821PubMedPubMedCentral Hsu T, Mitragotri S (2011) Delivery of sirna and other macromolecules into skin and cells using a peptide enhancer. Proc Natl Acad Sci U S A 108:15816–15821PubMedPubMedCentral
42.
Zurück zum Zitat Seidel EJ, Rother M, Regenspurger K, Rother I (2016) A randomised trial comparing the efficacy and safety of topical ketoprofen in transfersome gel (idea-033) with oral ketoprofen and drug-free ultra-deformable sequessome vesicles (tdt 064) for the treatment of muscle soreness following exercise. J Sports Sci 34:88–95PubMed Seidel EJ, Rother M, Regenspurger K, Rother I (2016) A randomised trial comparing the efficacy and safety of topical ketoprofen in transfersome gel (idea-033) with oral ketoprofen and drug-free ultra-deformable sequessome vesicles (tdt 064) for the treatment of muscle soreness following exercise. J Sports Sci 34:88–95PubMed
43.
Zurück zum Zitat Choi JH, Cho SH, Yun JJ, Yu YB, Cho CW (2015) Ethosomes and transfersomes for topical delivery of ginsenoside rhl from red ginseng: characterization and in vitro evaluation. J Nanosci Nanotechnol 15:5660–5662PubMed Choi JH, Cho SH, Yun JJ, Yu YB, Cho CW (2015) Ethosomes and transfersomes for topical delivery of ginsenoside rhl from red ginseng: characterization and in vitro evaluation. J Nanosci Nanotechnol 15:5660–5662PubMed
44.
Zurück zum Zitat Bracke S, Carretero M, Guerrero-Aspizua S, Desmet E, Illera N, Navarro M, Lambert J, Del Rio M (2014) Targeted silencing of DEFb4 in a bioengineered skin-humanized mouse model for psoriasis: Development of sirna secosome-based novel therapies. Exp Dermatol 23:199–201PubMed Bracke S, Carretero M, Guerrero-Aspizua S, Desmet E, Illera N, Navarro M, Lambert J, Del Rio M (2014) Targeted silencing of DEFb4 in a bioengineered skin-humanized mouse model for psoriasis: Development of sirna secosome-based novel therapies. Exp Dermatol 23:199–201PubMed
45.
Zurück zum Zitat Shah SM, Ashtikar M, Jain AS, Makhija DT, Nikam Y, Gude RP, Steiniger F, Jagtap AA, Nagarsenker MS, Fahr A (2015) Leciplex, invasomes, and liposomes: a skin penetration study. Int J Pharm 490:391–403PubMed Shah SM, Ashtikar M, Jain AS, Makhija DT, Nikam Y, Gude RP, Steiniger F, Jagtap AA, Nagarsenker MS, Fahr A (2015) Leciplex, invasomes, and liposomes: a skin penetration study. Int J Pharm 490:391–403PubMed
46.
Zurück zum Zitat Ingrole RSJ, Gill HS (2019) Microneedle coating methods: a review with a perspective. J Pharmacol Exp Ther 370:555–569PubMed Ingrole RSJ, Gill HS (2019) Microneedle coating methods: a review with a perspective. J Pharmacol Exp Ther 370:555–569PubMed
47.
Zurück zum Zitat Munch S, Wohlrab J, Neubert RHH (2017) Dermal and transdermal delivery of pharmaceutically relevant macromolecules. Eur J Pharm Biopharm 119:235–242PubMed Munch S, Wohlrab J, Neubert RHH (2017) Dermal and transdermal delivery of pharmaceutically relevant macromolecules. Eur J Pharm Biopharm 119:235–242PubMed
48.
Zurück zum Zitat Surber C, Kottner J (2017) Skin care products: what do they promise, what do they deliver. J Tissue Viability 26:29–36PubMed Surber C, Kottner J (2017) Skin care products: what do they promise, what do they deliver. J Tissue Viability 26:29–36PubMed
49.
Zurück zum Zitat Norlen L (2006) Stratum corneum keratin structure, function and formation—a comprehensive review. Int J Cosmet Sci 28:397–425PubMed Norlen L (2006) Stratum corneum keratin structure, function and formation—a comprehensive review. Int J Cosmet Sci 28:397–425PubMed
50.
Zurück zum Zitat Mizutani Y, Mitsutake S, Tsuji K, Kihara A, Igarashi Y (2009) Ceramide biosynthesis in keratinocyte and its role in skin function. Biochimie 91:784–790PubMed Mizutani Y, Mitsutake S, Tsuji K, Kihara A, Igarashi Y (2009) Ceramide biosynthesis in keratinocyte and its role in skin function. Biochimie 91:784–790PubMed
51.
Zurück zum Zitat Tessema EN, Gebre-Mariam T, Neubert RHH, Wohlrab J (2017) Potential application of phyto-derived ceramides in improving epidermal barrier function. Skin Pharmacol Physiol 30:115–138 Tessema EN, Gebre-Mariam T, Neubert RHH, Wohlrab J (2017) Potential application of phyto-derived ceramides in improving epidermal barrier function. Skin Pharmacol Physiol 30:115–138
52.
Zurück zum Zitat Neubert RHH, Sonnenberger S, Dobner B, Gray CW Jr, Barger KN, Sevi-Maxwell K, Sommer E, Wohlrab J (2016) Controlled penetration of a novel dimeric ceramide into and across the stratum corneum using microemulsions and various types of semisolid formulations. Skin Pharmacol Physiol 29:130–134PubMed Neubert RHH, Sonnenberger S, Dobner B, Gray CW Jr, Barger KN, Sevi-Maxwell K, Sommer E, Wohlrab J (2016) Controlled penetration of a novel dimeric ceramide into and across the stratum corneum using microemulsions and various types of semisolid formulations. Skin Pharmacol Physiol 29:130–134PubMed
53.
Zurück zum Zitat Wohlrab J, Gebert A, Neubert RHH (2018) Lipids in the skin and ph. Curr Probl Dermatol 54:64–70PubMed Wohlrab J, Gebert A, Neubert RHH (2018) Lipids in the skin and ph. Curr Probl Dermatol 54:64–70PubMed
54.
Zurück zum Zitat Caserta F, Brown MB, McAuley WJ (2019) The use of heat and chemical penetration enhancers to increase the follicular delivery of erythromycin to the skin. Eur J Pharm Sci 132:55–62PubMed Caserta F, Brown MB, McAuley WJ (2019) The use of heat and chemical penetration enhancers to increase the follicular delivery of erythromycin to the skin. Eur J Pharm Sci 132:55–62PubMed
55.
Zurück zum Zitat Cooley RL, Robison SF, Barkmeier WW (1980) Penetration of heat and cold application through vital tissue. Quintessence Int Dent Dig 11:87–92PubMed Cooley RL, Robison SF, Barkmeier WW (1980) Penetration of heat and cold application through vital tissue. Quintessence Int Dent Dig 11:87–92PubMed
57.
Zurück zum Zitat Lewis DJ, Chan WH, Hinojosa T, Hsu S, Feldman SR (2019) Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: a review. Clin Dermatol 37:160–166PubMed Lewis DJ, Chan WH, Hinojosa T, Hsu S, Feldman SR (2019) Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: a review. Clin Dermatol 37:160–166PubMed
58.
Zurück zum Zitat Niemeyer-van der Kolk T, van der Wall HEC, Balmforth C, Van Doorn MBA, Rissmann R (2018) A systematic literature review of the human skin microbiome as biomarker for dermatological drug development. Br J Clin Pharmacol 84:2178–2193PubMedPubMedCentral Niemeyer-van der Kolk T, van der Wall HEC, Balmforth C, Van Doorn MBA, Rissmann R (2018) A systematic literature review of the human skin microbiome as biomarker for dermatological drug development. Br J Clin Pharmacol 84:2178–2193PubMedPubMedCentral
60.
Zurück zum Zitat Subhan F, Shahzad R, Tauseef I, Haleem KS, Rehman AU, Mahmood S, Lee IJ (2018) Isolation, identification, and pathological effects of beach sand bacterial extract on human skin keratinocytes in vitro. PeerJ 6:e4245PubMedPubMedCentral Subhan F, Shahzad R, Tauseef I, Haleem KS, Rehman AU, Mahmood S, Lee IJ (2018) Isolation, identification, and pathological effects of beach sand bacterial extract on human skin keratinocytes in vitro. PeerJ 6:e4245PubMedPubMedCentral
Metadaten
Titel
Neue Entwicklungen bei Topika
verfasst von
Prof. Dr. Johannes Wohlrab
Publikationsdatum
11.11.2019
Verlag
Springer Medizin
Schlagwort
Wirkstoffe
Erschienen in
Die Dermatologie / Ausgabe 12/2019
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-019-04505-1

Weitere Artikel der Ausgabe 12/2019

Die Dermatologie 12/2019 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.